Stock Research: NovoCure

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

NovoCure

NasdaqGS:NVCR JE00BYSS4X48
6
  • Value
    24
  • Growth
    41
  • Safety
    Safety
    23
  • Combined
    4
  • Sentiment
    36
  • 360° View
    360° View
    6
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

NovoCure Limited is a global oncology company developing Tumor Treating Fields (TTFields) devices. The company operates in the medical device industry. It operates globally, with a license to market Optune in China, Hong Kong, Macau, and Taiwan. In the last fiscal year, the company had a market cap of $1,887 million, profits of $468 million, and revenue of $605 million, with 1488 employees.

more
Index
NASDAQ
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 18-Dec-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
24 20 27 11
Growth
41 80 19 55
Safety
Safety
23 7 25 12
Sentiment
36 30 1 10
360° View
360° View
6 9 1 1
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
71 51 28 3
Opinions Change
50 40 9 26
Pro Holdings
n/a 23 6 72
Market Pulse
46 63 12 38
Sentiment
36 30 1 10
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
24 20 27 11
Growth
41 80 19 55
Safety Safety
23 7 25 12
Combined
4 17 6 6
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
4 4 4 4
Price vs. Earnings (P/E)
53 27 46 3
Price vs. Book (P/B)
21 11 28 12
Dividend Yield
1 1 1 1
Value
24 20 27 11
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
30 1 33 52
Profit Growth
49 74 6 52
Capital Growth
100 100 98 90
Stock Returns
3 84 3 7
Growth
41 80 19 55
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
2 1 6 12
Refinancing
83 62 93 67
Liquidity
1 7 8 4
Safety Safety
23 7 25 12

Similar Stocks

Discover high‑ranked alternatives to NovoCure and broaden your portfolio horizons.

Drägerwerk

XTRA:DRW3
Country: Germany
Industry: Health Care Equipment
Size: Medium
Full Stock Analysis

Quilter

LSE:QLT
Country: United Kingdom
Industry: Asset Management & Custody
Size: Medium
Full Stock Analysis

Smith & Nephew

LSE:SN.
Country: United Kingdom
Industry: Health Care Equipment
Size: Large
Full Stock Analysis

Carl Zeiss Meditec

XTRA:AFX
Country: Germany
Industry: Health Care Equipment
Size: Medium
Full Stock Analysis

Frequently Asked
Questions

This is a highly risky stock investment proposition as all consolidated ranks are below-average. There are no compelling arguments to support this stock based on current information. It is not recommended for any investor profile. However, performance does change, so it could we worth keepin on a watchlist.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing: